Surface Oncology — Investor Presentation (January 2020)
39 slides from Surface Oncology's investor presentation, Jan 13, 2020
Slide 1: Breaking through for patients with cancer
Breaking through for patients with cancer January 2020 Exhibit 99.1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of ope
Slide 3: Break Through: strong foundation and mission
BREAK THROUGH Financial resources and strategic partners provide STRONG FOUNDATION On a mission to dramatically IMPROVE CURE RATES FOR CANCER Proven leadership and UNIQUELY COLLABORATIVE SCIENTIFIC ADVISORS Deep biological expertise across the TUMOR MICROENVIRONMENT Focus on differentiated targets b
Slide 4: Surface Oncology at a Glance
SURFACE ONCOLOGY. Surface Oncology at a Glance
Slide 5: Recent Corporate Highlights
Recent Corporate Highlights Filed INDs for SRF617 (CD39) and SRF388 (IL-27) New clinical candidate announced: SRF813, targeting CD112R Multiple poster presentations at SITC annual meeting Ramy Ibrahim, M.D. (CMO of the Parker Institute) added to the Board Cash at end of Q3 2019: $111.8 million
Slide 6: Broad Approach Targeting the Immunosuppressive Tumor Microenvironment
Block Suppressive Metabolites and Cytokines Activate Macrophages Deplete Regulatory T Cells Activate Natural Killer Cells Broad Approach Targeting the Immunosuppressive Tumor Microenvironment
Slide 7: Collaboration With Renowned Advisors
Collaboration With Renowned Advisors Oncology Immunology Translational science Clinical development A break through philosophy Transformative impact for patients Collective learning SCIENTIFIC ADVISORY BOARD SURFACE TEAM Deep expertise in: Commitment to: Sasha Rudensky, PhD Carla Rothlin, PhD John S
Slide 8: Broad Portfolio Targeting the Tumor Microenvironment
Broad Portfolio Targeting the Tumor Microenvironment
Slide 9: Overview of Ongoing Phase 1 Trial NZV930
Overview of Ongoing Phase 1 Trial NZV930 Single Agent Dose Escalation NZV930 with PDR001 (Anti-PD-1) NZV930 with NIR178 (A2AR antagonist) NZV930, NIR178 & PDR001 (1) NSCLC, TNBC, Ovarian Cancer, MSS Colorectal, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma Enrollment spanning three combinat
Slide 10: Management Team with Proven Track Record of Success
Rob Ross, MD Chief Medical Officer Vito Palombella, PhD Chief Scientific Officer Pam Holland, PhD Vice President, Cancer Biology Jeff Goater Chief Executive Officer Jessica Fees Senior Vice President, Finance and Business Operations Bob Steininger Senior Vice President, CMC Liisa Nogelo-Kerr General
Slide 11: Overview of SRF617 Targeting CD39 for Immune System Activation
Overview of SRF617 Targeting CD39 for Immune System Activation
Slide 12: Targeting CD39 Can Activate Both Innate and Adaptive Immunity
Targeting CD39 Can Activate Both Innate and Adaptive Immunity ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) (innate) NK cell T cell Myeloid cell Macrophage Dendritic cell
Slide 13: SRF617 Engages the Adaptive Immune System by Reducing Adenosine Levels
SRF617 Engages the Adaptive Immune System by Reducing Adenosine Levels ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) SRF617 SRF617 Reduces Plasma Adenosine Levels in Tumor-Bearing Mice SRF617
Slide 14: SRF617 Mediated CD39 Blockade is Immunostimulatory
14 ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) SRF617 SRF617 Mediated CD39 Blockade is Immunostimulatory By Reducing Adenosine Levels, SRF617 Stimulates T Cell Responses
Slide 15: SRF617 Engages the Innate Immune System By Increasing Extracellular ATP
15 Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Monotherapy or Combination with Gemcitabine Leads to Increased ATP Levels in Human Pancreatic Cancer Cultures * SRF617 Engages the Innate Immune System By Increasing Extracellular ATP
Slide 16: SRF617 Stimulates Key Components of the Innate Immune System
SRF617 Stimulates Key Components of the Innate Immune System 16 Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Stimulates Dendritic Cells, A Key Component of the Innate Immune System
Slide 17: CD39 Inhibition Demonstrates Potent Anti-tumor Activity
CD39 Inhibition Demonstrates Potent Anti-tumor Activity 17 SRF617 Single Agent Activity in Xenograft MOLP8 In Vivo Model Murine Anti-CD39 Surrogate Cooperates with Anti-PD1 in CT26 Model, Increasing Cures Days on Study 10/18 CR 4/16 CR (Rechallenge)
Slide 18: Patterns of CD39 TME Expression Lead to Translational Hypotheses
Patterns of CD39 TME Expression Lead to Translational Hypotheses in Tumor Types with High Clinical Need CD39 TIL expression CD39/CK Gastric CA CD39 CD39 stromal expression Pancreatic CA CD39/CK 18
Slide 19: CD39 Expression Increases After Anti-PD-(L)1 Exposure
CD39 Expression Increases After Anti-PD-(L)1 Exposure *Surface data 5 individual PBMC donors -/+ Nivolumab at 10ug/ml 96-Hour incubation Cell types and %CD39 expression determined by flow *Clinical data, Corvus, SITC 2017 CD39 expression analysis from RCC and NSCLC screening biopsies Resistant pts t
Slide 20: SRF617 Clinical Development Plan
SRF617 Clinical Development Plan Phase 1/1b 20 Dose Escalation: Patients with advanced solid tumors Establish safe monotherapy dose (accelerated & 3+3 design) Establish safe combination therapy dose(s); anticipate staggered start after monotherapy Biopsy Expansion Cohort: Evaluate on-target tumor ti
Slide 21: Key Phase 1 Bioassays to Assess Biologic POC
Key Phase 1 Bioassays to Assess Biologic POC 21 PBMC Target Occupancy CD39 Enzymatic Activity by IHC Allows for Direct Measurement of CD39 Inhibition within the TME Binding of SRF617 to PBMCs is Highly Correlated to Enzymatic Inhibition
Slide 22: SRF617 Antibody Targeting CD39
High affinity, fully human IgG4 antibody against human CD39 Potent inhibitor of enzymatic activity IND filed in November 2019 Dual mechanism of action: Significant reduction of adenosine and increased levels of ATP leads to increased T cell proliferation and dendritic cell maturation SRF617 Antibody
Slide 23: Overview of SRF388 Targeting IL-27 to Enhance Immune Activity in the TME
Overview of SRF388 Targeting IL-27 to Enhance Immune Activity in the TME
Slide 24: IL-27 is an Immunosuppressive Cytokine Upregulated During Pregnancy
IL-27 is an Immunosuppressive Cytokine Upregulated During Pregnancy, an Immune-tolerant State Detection of EBI3 (IL-27 subunit) in Serum
Slide 25: IL-27 Upregulates Checkpoint Receptors, Downregulates Proinflammatory Cytokines
IL-27 Upregulates Checkpoint Receptors, Downregulates Proinflammatory Cytokines IL-27 Receptor p28 Jak2 Jak1 STAT3 STAT1 Inflammatory Cytokines EBI3 IL-27 Ligand Inhibitory Receptors on Immune Cells IL-27 Upregulates Checkpoint Receptors IL-27 Downregulates Pro-Inflammatory Cytokines TNF⍺ +IL-27 Con
Slide 26: SRF388 Restores Cytokine Production in Combination with αPD-1
IL-27 SRF388 Restores Cytokine Production in Combination with αPD-1 in Presence of rIL-27 in Healthy Donor PBMCs IFNγ, TNFα, IL-17 T cell PD1 Control ⍺PD-1 IL-27 + ⍺PD-1 IL-27 + ⍺PD-1 + SRF388 Anti-PD-1 SRF388 Similar effects observed with IL-17 and TNFa Anti-PD-1
Slide 27: Levels of EBI3 are Elevated in Serum from Cancer Patients
Levels of EBI3 are Elevated in Serum from Cancer Patients
Slide 28: Evidence for IL-27 Pathway Activation in HCC and RCC
Evidence for IL-27 Pathway Activation in HCC and RCC P28 Expression in Hepatocellular Carcinoma U. Montreal Cohort - J. Stagg 187 RCC Plasma Samples Liver
Slide 29: SRF388 Inhibits Tumor Growth in an Orthotopic Model of HCC
SRF388 Inhibits Tumor Growth in an Orthotopic Model of Hepatocellular Carcinoma SRF388 (50 mg/kg) was dosed IP BIW x 2 Starting day 5 Tumor growth was measured by bioluminescent imaging Hepa1-6-Luc Tumors
Slide 30: SRF388 Clinical Development Plan Phase 1/1b
Potential to explore combinations in RCC Single arm Phase 2 in RCC Renal Cell Cancer Monotherapy dose expansion (Mandatory pre & post-treatment biopsies) Hepatocellular Cancer Monotherapy safety Potential to explore combinations in HCC Monotherapy dose escalation in patients with advanced solid tumo
Slide 31: Overview of SRF388: Potential First-in-Class Antibody Targeting IL-27
Overview of SRF388 Potential First-in-Class Antibody Targeting IL-27 High affinity, fully human IgG1 antibody against the p28 subunit of IL-27 IL-27 is a highly immunosuppressive cytokine upregulated during pregnancy and associated with maternal-fetal tolerance Targeted translational hypothesis: RCC
Slide 32: Overview of SRF813 Targeting CD112R to Enhance NK & T cell Activity
Overview of SRF813 Targeting CD112R to Enhance NK & T cell Activity in the TME
Slide 33: NK Focused Immunotherapies Provide a Strategy to Overcome Tumor Immune Resistance
NK Focused Immunotherapies Provide a Strategy to Overcome T Cell-Associated Tumor Immune Resistance Freeman, et al Cell Reports, 28, 2019 Genes that when depleted are associated with increased sensitivity to NK mediated killing Tumor cell NK cell MHC I low NK sensitivity Genes that when depleted pro
Slide 34: The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation
The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation NK cell Tumor cell CD112 PBMC-NK activation assay NK degranulation assay Raji.CD112 Cells K562 Cells SRF813 + + activation + + + CD16 CD112R CD226
Slide 35: SRF813 Has the Potential for Improved Efficacy
SRF813 Has the Potential for Improved Efficacy In vitro NK cell activity assay K562 Cells CD16 CD112R Distinct epitope and isotype important for functional activity Competitor Model for SRF813 binding CD112 SRF813 + Tumor cell NK Cell CD226 + - CT26 syngeneic tumor model muIgG1 = low affinity bindin
Slide 36: CD112R Antibody Delays Tumor Growth and Promotes Immunological Memory
CD112R Antibody Delays Tumor Growth and Promotes Immunological Memory Anti-muCD112R 25 mg/kg, starting day 4 (BIW x 3) Anti-tumor activity as a single agent Naive Re-challenged Tumor free re-challenged display immunological memory Activity is NK and T cell dependent Isotype anti-muCD112R
Slide 37: SRF813 Antibody Targeting CD112R
High affinity, fully human IgG1 antibody against human CD112R NK cell targeted therapies have the potential to overcome PD-1 resistance SRF813 represents a new therapeutic approach designed to enhance NK/T cell activation in the TME SRF813 enhances NK cell and T cell activation via a distinct mechan
Slide 38: Upcoming Milestones
IND-enabling work ongoing PROGRAM CANDIDATE KEY NEAR TERM MILESTONES Initial Phase 1 results Combinations with anti-PD-1 and A2AR Initiate Phase 1 in early 2020 Initial clinical update in late 2020 Initiate Phase 1 in early 2020 Initial clinical update in late 2020 Upcoming Milestones Next Wave of P
Slide 39: Breaking through for patients with cancer
Breaking through for patients with cancer
Surface Oncology — Investor Presentation (January 2020) on 6ix